Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

14.06 -4.78 (-25.37%)
Streaming Delayed Price Updated: 1:59 PM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,523,491
Open 18.50
Bid (Size) 14.06 (100)
Ask (Size) 14.10 (600)
Prev. Close 18.84
Today's Range 13.62 - 18.50
52wk Range 9.900 - 34.29
Shares Outstanding 9,587,155
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that... 
Via MarketMinute
Topics Intellectual Property

Performance

YTD
-54.2%
-54.2%
1 Month
-50.4%
-50.4%
3 Month
-53.4%
-53.4%
6 Month
-32.5%
-32.5%
1 Year
+19.4%
+19.4%

More News

Read More
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
Here are the top movers in Monday's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Monday's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
Via The Motley Fool
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
Via The Motley Fool
News headline image
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Prepares for Transformational 2026
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Inc (NASDAQ:VRDN) Shows High-Growth Momentum and Strong Technical Setup ↗
Via Chartmill
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
From Viridian Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Viridian Therapeutics, Inc. - Common Stock publicly traded?
Yes, Viridian Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Viridian Therapeutics, Inc. - Common Stock trade on?
Viridian Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Viridian Therapeutics, Inc. - Common Stock?
The ticker symbol for Viridian Therapeutics, Inc. - Common Stock is VRDN on the Nasdaq Stock Market
What is the current price of Viridian Therapeutics, Inc. - Common Stock?
The current price of Viridian Therapeutics, Inc. - Common Stock is 14.06
When was Viridian Therapeutics, Inc. - Common Stock last traded?
The last trade of Viridian Therapeutics, Inc. - Common Stock was at 04/06/26 01:59 PM ET
What is the market capitalization of Viridian Therapeutics, Inc. - Common Stock?
The market capitalization of Viridian Therapeutics, Inc. - Common Stock is 134.80M
How many shares of Viridian Therapeutics, Inc. - Common Stock are outstanding?
Viridian Therapeutics, Inc. - Common Stock has 135M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS